Efficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in Allergic Conjunctivitis

NCT00882687 | Completed Phase 2 Results

• 1 other identifier: 1118-ACJ-100
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to determine whether SAR 1118 at three different concentrations, compared to placebo, is effective in the prevention of the signs and symptoms of allergic conjunctivitis

Conditions

Allergic Conjunctivitis

Outcome Measures

Primary Outcomes (4)

• Ocular Itching at Day 7 (7 Minutes Post Conjunctival Allergen Challenge [CAC 6])

  Ocular Itching was evaluated by participants and graded with Ophthalmic Research Associates, Inc. (ORA) Scale with the score ranged from 0 to 4 (0=none; 0.5=intermittent tickle in the cornea; 1=intermittent tickle more than just the cornea; 1.5=intermittent all-over tickling sensation; 2=mild conscious itch without desire to rub; 2.5=moderate, diffuse continuous itch with desire to rub; 3=severe itch with desire to rub; 3.5=severe itch improved with minimal rubbing; 4=incapacitating itch with an irresistible urge to rub) with 0.5 point increments allowed, and lower scores indicates lesser ocular itching. CAC is an initial titration challenge to determine the appropriate allergen and lowest concentration of allergen that produced a positive bilateral allergic response for each subject, defined as ≥ 2 score (0-4 point scale) in ocular itching and conjunctival redness within 10 minutes of the last titration of allergen.

  Baseline to Day 7 (7 minutes post CAC 6)

• Ocular Itching at Day 14 (7 Minutes Post CAC 9)

  Ocular Itching was evaluated by participants and graded with Ophthalmic Research Associates, Inc. (ORA) Scale with the score ranged from 0 to 4 (0=none; 0.5=intermittent tickle in the cornea; 1=intermittent tickle more than just the cornea; 1.5=intermittent all-over tickling sensation; 2=mild conscious itch without desire to rub; 2.5=moderate, diffuse continuous itch with desire to rub; 3=severe itch with desire to rub; 3.5=severe itch improved with minimal rubbing; 4=incapacitating itch with an irresistible urge to rub) with 0.5 point increments allowed, and lower scores indicates lesser ocular itching.

  Baseline to Day 14 (7 minutes post CAC 9)

• Conjunctival Redness at Day 7 (20 Minutes Post CAC 6)

  Conjunctival Redness was evaluated by an investigator with slit lamp and graded with ORA Scale with the score ranged from 0 to 4 (0=none; 1=mild-slightly dilated blood vessels; color of vessels is typically pink; can be quadrantal; 2=moderate-more apparent dilation of blood vessels; vessel color is more intense (redder); involves the majority of the vessel bed; 3=severe-numerous and obvious dilated blood vessels; in the absence of chemosis the color is deep red, may be less red or pink in presence of chemosis, is not quadrantic; 4=extremely severe-large, numerous, dilated blood vessels characterized by unusually severe deep red color, regardless of grade of chemosis, which involves the entire vessel bed) with 0.5 point increments allowed, and lower scores indicates reduction in the conjunctival redness.

  Baseline to Day 7 (20 minutes post CAC 6)

• Conjunctival Redness at Day 14 (20 Minutes Post CAC 9)

  Conjunctival Redness was evaluated by an investigator with slit lamp and graded with ORA Scale with the score ranged from 0 to 4 (0=none; 1=mild-slightly dilated blood vessels; color of vessels is typically pink; can be quadrantal; 2=moderate-more apparent dilation of blood vessels; vessel color is more intense (redder); involves the majority of the vessel bed; 3=severe-numerous and obvious dilated blood vessels; in the absence of chemosis the color is deep red, may be less red or pink in presence of chemosis, is not quadrantic; 4=extremely severe-large, numerous, dilated blood vessels characterized by unusually severe deep red color, regardless of grade of chemosis, which involves the entire vessel bed) with 0.5 point increments allowed, and lower scores indicates reduction in the conjunctival redness.

  Baseline to Day 14 (20 minutes post CAC 9)

Secondary Outcomes (2)

• Ocular Itching at Day 6 (CAC 4), 5 (CAC 7)

  Baseline to Day 6 (CAC 4), Day 13 (CAC 7) 7 minutes post CAC

• Conjunctival Redness at Day 6 (CAC 4), 5 (CAC 7)

  Baseline to Day 6 (CAC 4), Day 13 (CAC 7) at 20 minutes post CAC

Study Arms (4)

0.1% Lifitegrast

EXPERIMENTAL

Drug: Lifitegrast

1.0% Lifitegrast

EXPERIMENTAL

Drug: Lifitegrast

5.0% Lifitegrast

EXPERIMENTAL

Drug: Lifitegrast

Placebo

PLACEBO COMPARATOR

Other: Placebo

Interventions

Lifitegrast DRUG

Ophthalmic Solution

Also known as: SAR 1118

0.1% Lifitegrast; 1.0% Lifitegrast; 5.0% Lifitegrast

Placebo OTHER

Ophthalmic Solution

Placebo

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Signed informed consent form and HIPAA document
• Willing and able to comply with all study procedures
• Be at least 18 years of age at the time of enrollment
• /40 vision, or better, in each eye
• History of ocular allergies, and a positive skin and ocular allergic reaction to allergens
• A negative urine pregnancy test if female of childbearing potential and must use adequate birth control throughout the study period

You may not qualify if:

• Preauricular lymphadenopathy or any ocular condition that could affect study parameters (particularly, glaucoma, diabetic retinopathy, clinically significant blepharitis, follicular conjunctivitis and iritis)
• Have had any ocular infection within the last 30 days
• A positive diagnosis of moderate to severe dry eye syndrome (i.e., requiring daily use of artificial tears)
• Any significant illness that could be expected to interfere with study parameters
• Manifest signs or symptoms of clinically active allergic conjunctivitis in either eye
• Use of any investigational product or device within one month prior to Visit 1 or during the study period
• Concomitant use of any prohibited medication (antihistamines, corticosteroids, all ocular medications or anti-allergic therapies) during the trial or within the washout period
• Any blood donation or significant loss of blood within 56 days of Visit 1
• Any history of autoimmune disease, immunodeficiency disorder, positive HIV, hepatitis B, C, or evidence of acute active hepatitis A (anti-HAV IgM), or organ or bone marrow transplant. Any known history of iritis/uveitis, glaucoma, or other chronic ophthalmologic disorder other than allergic conjunctivitis
• History of laser-assisted in situ keratomileusis (LASIK) or similar type of corneal refractive surgery within 12 months prior to Visit 1, and/or any other ocular surgical procedure within 3 months prior to Visit 1
• Known history of alcohol abuse and/or drug abuse

Sponsors & Collaborators

• Shire: lead

Study Sites (1)

Ora

Andover, Massachusetts, 01810, United States

Location

MeSH Terms

Conditions

Conjunctivitis, Allergic

Interventions

lifitegrast

Condition Hierarchy (Ancestors)

Conjunctivitis; Conjunctival Diseases; Eye Diseases; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Results Point of Contact

• Title: Study Director
• Organization: Shire (Note: Lifitegrast was divested to Novartis in 2019)

ClinicalTransparency@shire.com

+1 866 842 5335

Study Officials

• Study Director

  Takeda

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 15, 2009
• First Posted: April 16, 2009
• Study Start: April 24, 2009
• Primary Completion: May 10, 2009
• Study Completion: May 10, 2009
• Last Updated: June 11, 2021
• Results First Posted: February 24, 2017

Record last verified: 2021-06

Locations

US (1)